Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

BACKGROUND: Targeting angiogenesis is nowadays one of the most promising approaches for breast cancer. Bevacizumab (BEV), a VEGF-trap monoclonal antibody, was recently approved in combination with paclitaxel (PAC) for the first line treatment of advanced breast cancer (ABC). The activity of this com...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardavanis, Alexandros, Doufexis, Dimitrios, Kountourakis, Panteleimon, Malliou, Savvoula, Karagiannis, Athanasios, Kardara, Evgenia, Sykoutri, Despina, Charalampia, Margari, Rigatos, Gerasimos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759965/
https://www.ncbi.nlm.nih.gov/pubmed/19775466
http://dx.doi.org/10.1186/1471-2407-9-338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759965/
https://www.ncbi.nlm.nih.gov/pubmed/19775466
http://dx.doi.org/10.1186/1471-2407-9-338

Ejemplares similares